Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI

Dyslipidemia is listed among important cardiovascular disease risk factors. Treating lipid disorders is difficult, and achieving desirable levels of LDL-cholesterol (LDL-C) is essential in both the secondary and primary prevention of cardiovascular disease. For many years, statins became the basis of lipid-lowering therapy. Nevertheless, these drugs are often insufficient due to their side effects and restrictive criteria for achieving the recommended LDL-C values. Even the addition of other drugs, i.e., ezetimibe, does not help one achieve the target LDL-C. The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) discovery has triggered intensive research on a new class of protein-based drugs. The protein PCSK9 is located mainly in hepatocytes and is involved in the metabolism of LDL-C. In the beginning, antibodies against the PCSK9 protein, such as evolocumab, were invented. The next step was inclisiran. Inclisiran is a small interfering RNA (siRNA) that inhibits the expression of PCSK9 by binding specifically to the mRNA precursor of PCSK9 protein and causing its degradation. It has been noticed in recent years that siRNA is a powerful tool for biomedical research and drug discovery. The purpose of this work is to summarize the molecular mechanisms, pharmacokinetics, pharmacodynamics of inclisiran and to review the latest research.

Ann Transl Med. 2018 Apr;6(7):130. (PMID: 29955590)
N Engl J Med. 2020 Apr 16;382(16):1507-1519. (PMID: 32187462)
Drugs. 2021 May;81(7):841-848. (PMID: 33871817)
FASEB J. 2006 Jul;20(9):1293-9. (PMID: 16816104)
Cell. 2009 Feb 20;136(4):642-55. (PMID: 19239886)
Nature. 2000 Mar 16;404(6775):293-6. (PMID: 10749213)
Sci China Life Sci. 2020 Apr;63(4):485-500. (PMID: 31054052)
Medicina (Kaunas). 2022 Nov 17;58(11):. (PMID: 36422206)
Acta Cardiol Sin. 2016 Nov;32(6):631-639. (PMID: 27899849)
J Clin Med. 2021 Jun 02;10(11):. (PMID: 34199468)
Biomed Res Int. 2013;2013:928271. (PMID: 23841099)
Int J Mol Sci. 2020 Dec 30;22(1):. (PMID: 33396592)
J Am Heart Assoc. 2022 Feb;11(3):e023328. (PMID: 35048716)
Atherosclerosis. 2018 Sep;276:124-130. (PMID: 30059843)
J Clin Med. 2021 Jun 05;10(11):. (PMID: 34198795)
Circulation. 2017 Jan 24;135(4):338-351. (PMID: 27941065)
Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. (PMID: 28927706)
Eur Heart J. 2020 Jun 21;41(24):2332. (PMID: 32031600)
Nurse Pract. 2018 Oct;43(10):22-29. (PMID: 30153192)
Biomed Pharmacother. 2022 Dec;156:113957. (PMID: 36411665)
Circulation. 2016 Jan 26;133(4):e38-360. (PMID: 26673558)
Nat Genet. 2003 Jun;34(2):154-6. (PMID: 12730697)
J Clin Lipidol. 2020 Jan - Feb;14(1):16-27. (PMID: 31879073)
Circ Res. 2017 Mar 31;120(7):1063-1065. (PMID: 28264867)
Curr Atheroscler Rep. 2022 Nov;24(11):831-838. (PMID: 36066785)
N Engl J Med. 2014 May 8;370(19):1809-19. (PMID: 24678979)
Drugs. 2018 Oct;78(15):1625-1631. (PMID: 30251172)
Genet Med. 2022 Mar;24(3):654-662. (PMID: 34906487)
Lancet Diabetes Endocrinol. 2023 Feb;11(2):109-119. (PMID: 36620965)
J Cardiovasc Dev Dis. 2020 Oct 15;7(4):. (PMID: 33076542)
Cardiovasc Ther. 2022 Feb 10;2022:8129513. (PMID: 35237348)
Clinicoecon Outcomes Res. 2022 Apr 05;14:189-203. (PMID: 35411162)
Lancet Diabetes Endocrinol. 2022 Oct;10(10):732-740. (PMID: 36075246)
Diabetes Care. 2019 Jan;42(1):173-176. (PMID: 30487231)
Molecules. 2021 Jun 04;26(11):. (PMID: 34200064)
Cell Chem Biol. 2022 Feb 17;29(2):249-258.e5. (PMID: 34547225)
Molecules. 2022 Dec 01;27(23):. (PMID: 36500502)
S Afr Med J. 2022 May 31;112(6):426-432. (PMID: 36217872)
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188581. (PMID: 34144130)
Int J Mol Sci. 2021 Jun 02;22(11):. (PMID: 34199647)
Curr Atheroscler Rep. 2022 Oct;24(10):803-811. (PMID: 35877035)
Expert Opin Drug Metab Toxicol. 2021 Dec;17(12):1353-1361. (PMID: 35025707)
N Engl J Med. 2020 Jun 11;382(24):2289-2301. (PMID: 32521132)
Circulation. 2011 Nov 15;124(20):2202-7. (PMID: 21986285)
N Engl J Med. 2017 Jan 5;376(1):41-51. (PMID: 27959715)
N Engl J Med. 2020 Apr 16;382(16):1520-1530. (PMID: 32197277)
Nat Rev Cardiol. 2022 Mar;19(3):147. (PMID: 35079155)
Biomed Pharmacother. 2022 Sep;153:113391. (PMID: 36076524)
N Engl J Med. 2022 Nov 17;387(20):1855-1864. (PMID: 36342163)
N Engl J Med. 2017 Apr 13;376(15):1430-1440. (PMID: 28306389)
N Engl J Med. 2018 Nov 29;379(22):2097-2107. (PMID: 30403574)
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928-33. (PMID: 12552133)
J Am Chem Soc. 2014 Dec 10;136(49):16958-61. (PMID: 25434769)
N Engl J Med. 2020 Aug 20;383(8):711-720. (PMID: 32813947)
Lancet Neurol. 2021 Jan;20(1):49-59. (PMID: 33212063)
Biomed Pharmacother. 2021 Nov;143:112227. (PMID: 34563953)
N Engl J Med. 2017 May 4;376(18):1713-1722. (PMID: 28304224)
BioDrugs. 2020 Feb;34(1):1-9. (PMID: 31782112)
N Engl J Med. 2006 Dec 7;355(23):2391-3. (PMID: 17151363)
Circulation. 2019 Jan 22;139(4):431-443. (PMID: 30586695)
Ann Intern Med. 2013 Apr 2;158(7):526-34. (PMID: 23546564)
Amyloid. 2022 Jul 23;:1-9. (PMID: 35875890)
Nat Med. 2022 Jan;28(1):96-103. (PMID: 35027752)
J Thromb Haemost. 2021 Jun;19(6):1436-1446. (PMID: 33587824)
Nature. 1998 Feb 19;391(6669):806-11. (PMID: 9486653)
Nat Rev Drug Discov. 2007 Jun;6(6):443-53. (PMID: 17541417)
Mayo Clin Proc. 2020 Jan;95(1):77-89. (PMID: 31630870)
Eur Heart J. 2015 Oct 21;36(40):2696-705. (PMID: 26306399)
Endocr Rev. 2022 May 12;43(3):558-582. (PMID: 35552680)
Circulation. 2017 Jan 24;135(4):352-362. (PMID: 27986651)
N Engl J Med. 2020 Oct 1;383(14):1317-1327. (PMID: 32865373)
N Engl J Med. 2017 Apr 20;376(16):1527-1539. (PMID: 28304242)
Curr Cardiol Rep. 2020 Oct 21;22(12):176. (PMID: 33089390)
Circ Cardiovasc Qual Outcomes. 2017 Jul;10(7):. (PMID: 28698192)
Expert Opin Investig Drugs. 2018 Mar;27(3):287-294. (PMID: 29451410)
Eur J Prev Cardiol. 2022 Jul 20;29(9):1361-1368. (PMID: 35175352)
Curr Opin Genet Dev. 2010 Feb;20(1):91-5. (PMID: 19962879)
Clin Cancer Res. 2015 Mar 15;21(6):1383-94. (PMID: 25589625)
N Engl J Med. 2021 Apr 1;384(13):1216-1226. (PMID: 33789010)
J Clin Med. 2022 Nov 16;11(22):. (PMID: 36431249)
Eur Heart J. 2016 May 01;37(17):1373-9. (PMID: 26916794)
Drugs. 2020 Feb;80(3):335-339. (PMID: 32034693)
Methods Enzymol. 2005;392:278-96. (PMID: 15644187)
Neurol Ther. 2020 Dec;9(2):301-315. (PMID: 32785879)
Curr Atheroscler Rep. 2022 Jul;24(7):547-556. (PMID: 35499807)
J Clin Lipidol. 2016 Jan-Feb;10(1 Suppl):S1-43. (PMID: 26891998)
Drugs. 2021 Feb;81(3):389-395. (PMID: 33620677)
Cardiovasc Res. 2021 Jan 1;117(1):284-291. (PMID: 32243492)
Am J Kidney Dis. 2023 Feb;81(2):145-155.e1. (PMID: 35843439)
Endocr Metab Immune Disord Drug Targets. 2022;22(14):1367-1377. (PMID: 35538809)
Biomed Pharmacother. 2022 Mar;147:112618. (PMID: 35051864)
Eur Heart J. 2020 Jan 1;41(1):111-188. (PMID: 31504418)
J Pediatr Health Care. 2019 Jul - Aug;33(4):494-504. (PMID: 31227123)
BMJ Open. 2016 Mar 30;6(3):e010500. (PMID: 27029774)
Int J Mol Sci. 2021 May 30;22(11):. (PMID: 34070931)
Lancet Diabetes Endocrinol. 2022 Oct;10(10):686-688. (PMID: 36075245)
J Clin Lipidol. 2018 Sep - Oct;12(5):1199-1207. (PMID: 30318065)
J Clin Lipidol. 2022 Mar-Apr;16(2):208-219. (PMID: 35168913)
Expert Opin Pharmacother. 2020 Nov;21(16):1971-1974. (PMID: 32749892)
Nat Rev Cancer. 2017 Aug;17(8):502-508. (PMID: 28643779)
Mayo Clin Proc. 2020 Jan;95(1):12-14. (PMID: 31902406)
J Lipid Res. 2021;62:100130. (PMID: 34606887)
Atherosclerosis. 2019 Nov;290:140-205. (PMID: 31591002)
Expert Opin Investig Drugs. 2018 Apr;27(4):421-426. (PMID: 29569947)
J Clin Oncol. 2011 Feb 20;29(6):747-54. (PMID: 21079135)
JAMA Cardiol. 2017 Jun 1;2(6):598-607. (PMID: 28291870)
Microvasc Res. 2019 Jan;121:24-29. (PMID: 30218671)
ACS Pharmacol Transl Sci. 2022 Sep 21;5(11):1007-1016. (PMID: 36407951)
Drugs Context. 2021 Nov 01;10:. (PMID: 34795777)

Keywords: PCSK9; atherosclerosis; dyslipidemia; inclisiran; siRNA

Date Created: 20230225 Latest Revision: 20230301

20230301

PMC9965021

10.3390/pharmaceutics15020323

36839644